By Lisa Kerner
Erie, Pa., April 20 - Sirtris Pharmaceuticals said it completed a $15 debt financing in addition to the recent $22 million series C equity the company raised.
Proceeds from the financing will be used to accelerate Sirtris' therapeutic programs.
Hercules Technology Growth Capital, Inc. led the round.
Located in Cambridge, Mass., Sirtris is a biopharmaceutical company developing novel therapeutics using sirtuins (enzymes) to treat disease.
| Issuer: | Sirtris Pharmaceuticals
|
| Issue: | Debt financing
|
| Amount: | $15 million
|
| Investor: | Hercules Technology Growth Capital, Inc.
|
| Announcement date: | April 20
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
